Coagulation and Microvascular Dynamics
Emerging evidence implicates microclot formation and endothelial dysfunction in ME/CFS and post-COVID fatigue. Microclots—amyloid fibrin(ogen) aggregates resistant to normal fibrinolysis—can obstruct capillaries, impairing tissue oxygenation. This section develops a coagulation model that couples to the oxygen delivery equation (Integrated Multi-System Models) and the immune model.
1 Coagulation Cascade Model
The model tracks the balance between clot formation and dissolution through four aggregate variables: fibrinogen (\([\text{Fbg}]\)), fibrin (\([\text{Fbn}]\)), microclot burden (\(M_c\)), and plasmin activity (\([\text{Pls}]\)):
\[ \begin{aligned} \frac{d [\text{Fbn}]}{d t} &= k_{\text{thrombin}} \cdot [\text{Fbg}] \cdot f_{\text{TF}}(\mathbf{C}_{\text{pro}}, \text{endothelial damage}) - k_{\text{lysis}} \cdot [\text{Pls}] \cdot [\text{Fbn}] \\ \frac{d M_c}{d t} &= k_{\text{aggregate}} \cdot [\text{Fbn}]^2 - k_{\text{resolve}} \cdot [\text{Pls}] \cdot \frac{M_c}{K_{\text{resist}} + M_c} \\ \frac{d [\text{Pls}]}{d t} &= k_{\text{tPA}} - k_{\text{PAI1}} \cdot [\text{PAI-1}] \cdot [\text{Pls}] - \delta_{\text{Pls}} [\text{Pls}] \end{aligned} \tag{1}\]
where \(f_{\text{TF}}\) is the tissue factor expression function (upregulated by pro-inflammatory cytokines and endothelial damage), \(k_{\text{aggregate}}\) is the rate of fibrin self-assembly into amyloid-like structures (quadratic in fibrin, reflecting cooperative aggregation), and \(K_{\text{resist}}\) parameterizes the resistance of amyloid microclots to plasmin-mediated dissolution. The PAI-1 (plasminogen activator inhibitor-1) concentration \([\text{PAI-1}]\) is elevated in inflammatory states, inhibiting plasmin and impairing fibrinolysis.
2 Coupling to Oxygen Delivery
Microclots reduce effective capillary perfusion, modifying the oxygen delivery equation (o2 delivery):
\[ \text{DO}_2^{\text{eff}} = \text{DO}_2 \cdot (1 - \frac{M_c}{M_{c,\text{max}}})^{\eta} \tag{2}\]
where \(\eta > 1\) reflects the nonlinear relationship between capillary occlusion and tissue oxygenation (due to the heterogeneous distribution of microclots across the vascular bed). This coupling produces a result uniquely derivable from the mathematical model: the combined effect of reduced cardiac output (autonomic dysfunction), impaired oxygen extraction (mitochondrial dysfunction), and capillary occlusion (microclots) on tissue VO₂ is multiplicative, not additive. A patient with individually modest impairments in all three—say, 20% reduced CO, 15% reduced ETC capacity, and 10% capillary occlusion—experiences an effective VO₂ reduction of approximately $ 1 - (0.8 ) %$, far exceeding the sum of individual impairments. This multiplicative interaction explains why ME/CFS patients with seemingly mild abnormalities on individual tests can have profound functional impairment.
3 Endothelial Dysfunction Model
Endothelial cells regulate vascular tone through nitric oxide (NO) production by endothelial NO synthase (eNOS). Endothelial dysfunction—reduced NO bioavailability—contributes to both microvascular impairment and coagulation activation. The eNOS model tracks NO production as a function of cofactor availability:
\[ J_{\text{eNOS}} = v_{\text{eNOS}} \cdot \frac{[\text{Arg}]}{K_{\text{Arg}} + [\text{Arg}]} \cdot \frac{[\text{BH}_4]}{K_{\text{BH}_4 \text{,eNOS}} + [\text{BH}_4]} \cdot \frac{K_{\text{ADMA}}}{K_{\text{ADMA}} + [\text{ADMA}]} \tag{3}\]
where \([\text{Arg}]\) is L-arginine (substrate), \([\text{BH}_4]\) is tetrahydrobiopterin (essential cofactor), and \([\text{ADMA}]\) is asymmetric dimethylarginine (endogenous eNOS inhibitor, elevated in inflammatory states). When \([\text{BH}_4]\) is depleted, eNOS “uncouples”—producing superoxide instead of NO, worsening oxidative stress. The BH₄ competition with tryptophan hydroxylase and tyrosine hydroxylase (Neuroendocrine and Autonomic Models, tryptophan and catecholamines) creates a three-way resource conflict discussed further in Tetrahydrobiopterin Competition Model.
Reduced NO shifts the coagulation balance toward clot formation (NO normally inhibits platelet aggregation and tissue factor expression), completing a vicious cycle: inflammation \(->\) BH₄ depletion \(->\) eNOS uncoupling \(->\) reduced NO \(->\) increased coagulation \(->\) microclots \(->\) tissue hypoxia \(->\) further inflammation. The model predicts that fibrinolytic agents (nattokinase, lumbrokinase) should improve tissue oxygenation, and that L-arginine supplementation alone will be ineffective when BH₄ is the rate-limiting cofactor—a distinction that requires the model to adjudicate.
Microclot accumulation acts as a disease amplifier by reducing tissue oxygenation below the threshold required for adequate mitochondrial function. Because microclot formation is driven by inflammation (upstream) and impairs oxygenation (downstream), it amplifies the energy–immune vicious cycle without being a primary cause. This amplifier role predicts that: (1) anti-coagulant or fibrinolytic therapy should produce improvement in ME/CFS patients with elevated D-dimer or microclot burden, without achieving cure (because the primary feedback loop persists); (2) the magnitude of improvement should correlate with baseline microclot burden; and (3) withdrawal of fibrinolytic therapy should produce relapse as microclots re-accumulate.
Certainty: 0.30. Direct evidence for pathogenic microclots in ME/CFS (as distinct from post-COVID) remains limited. The role of coagulation abnormalities as cause versus consequence of the inflammatory state is unresolved.